Targeting Drug Resistance Challenges, Nanolattix's HER2/TF Bispecific ADC B836 Selected for AACR Session

Research findings related to B836, a bispecific antibody-drug conjugate (ADC) independently developed by Nanolattix, have been selected for the "Drug Resistance: Antibodies and ADCs" session at the 2026 American Association for Cancer Research (AACR) Annual Meeting and will be presented during the conference.
As a first-in-class (FIC) bispecific ADC, B836 targets both HER2 and tissue factor (TF) simultaneously, featuring a clearly differentiated design within the current landscape of similar pipelines. Both HER2 and TF are highly expressed in various solid tumors and have been validated as druggable targets. More importantly, HER2 and TF are co-expressed in several highly prevalent malignant tumor types, including breast cancer, non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer, and esophageal cancer, among others.
Leveraging the synergistic recognition mechanism of dual targets, B836 is expected to enhance tumor cell coverage in the context of tumor heterogeneity, thereby offering a new approach to address drug resistance. B836 is a core pipeline asset that Nanolattix will prioritize advancing, representing a key product with significant potential clinical and commercial value within its current pipeline.

In recent years, ADC therapies, exemplified by Enhertu (trastuzumab deruxtecan, DS8201), have largely reshaped the technological expectations for solid tumor treatment. From HER2-positive breast cancer to broader indications with low expression, ADCs have achieved a critical transition from "precise targeting" to "broad applicability." However, as clinical application deepens, drug resistance arising from downregulation of target expression and inter-tumoral heterogeneity has gradually emerged as a central challenge limiting sustained efficacy.
As one of the most influential academic conferences in the field of global oncology research, AACR has in recent years established "drug resistance" as a core theme, dividing it into multiple sessions. This reflects that as innovative therapies like ADCs enter deeper stages of clinical application, the focus is shifting from "whether it works" to "why it fails" and "how to sustain efficacy."
Based on the research directions unveiled at this year's AACR, exploration surrounding ADC resistance is intensifying: on one hand, a significant body of research focuses on elucidating resistance mechanisms and model construction; on the other hand, differentiated designs such as dual-payload ADCs and dual-target ADCs are rapidly emerging, aiming to enhance depth of response and patient coverage at the molecular level. Against this backdrop, molecular design oriented towards addressing resistance is becoming a key exploratory direction for next-generation ADCs.
B836 is precisely an FIC bispecific ADC product developed under this rationale. By simultaneously targeting HER2 and TF, this molecule aims to enhance tumor cell recognition and binding capacity in the context of heterogeneous target expression. Preclinical study results show that B836 exhibits significantly enhanced tumor cell binding and internalization capabilities in in vitro models. In in vivo studies, it also demonstrated superior anti-tumor activity compared to single-target ADCs, maintaining good efficacy particularly in low HER2 expression models. Its tumor growth inhibition efficacy was superior to DS8201, suggesting potential advantages in overcoming certain primary or acquired resistance mechanisms.
Regarding safety, researchers conducted GLP toxicology and toxicokinetic (TK) evaluations in cynomolgus monkeys. The results showed no observed systemic toxicity within a certain dose range, indicating a favorable overall safety profile, which lays the foundation for its subsequent clinical development.
As oncology treatment advances into deeper waters, a single technological pathway is no longer sufficient to simultaneously address multiple challenges such as heterogeneity and drug resistance. How to maintain killing efficacy within a complex context while achieving a more precise understanding of a drug's in vivo mechanism of action is becoming a central question for the industry.
Based on this, Nanolattix has established an innovative system of multi-pathway synergy, proposing a strategy for the synergistic development of ADC and radionuclide drug conjugate (RDC) based on "same target, same antibody ligand," along with a theranostics approach. This achieves the synergistic design of diagnosis and therapy at the molecular level to enhance therapeutic certainty and precision. This strategic layout also reflects its systematic understanding of tumor complexity.
Within this framework, B836 is not only being advanced as a bispecific ADC drug, but its corresponding RDC format is also under parallel development. Data from animal model studies on the B836-RDC therapeutic radiopharmaceutical have been obtained. Imaging studies have validated the specific enrichment and favorable spatiotemporal distribution characteristics of this dual-target molecule in tumor models, providing foundational support for the subsequent theranostics strategy and clinical translation.
Meanwhile, research related to RT01 from Nanolattix's radiopharmaceutical RDC pipeline has been selected for this year's AACR session on "Radiopharmaceutical Platforms and Theranostic Precision Oncology." This drug has already entered the investigator-initiated trial (IIT) stage, gaining further recognition at the academic level.
The next-generation ADC represented by B836 is now advancing synergistically with the RDC pathway, marking that Nanolattix's integrated therapeutic system centered on "precise identification, dynamic assessment, and multi-mechanism intervention" has entered the substantive development stage.

Note: The data presented in this article are from preclinical studies and do not constitute a guarantee of efficacy.